News

Video

What's Next in Immunotherapy?

Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.

Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.

During the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting & Associated Programs, Capitini emphasized that all cancers should eventually find benefit in immunotherapy. With expansion in renal cell carcinoma (RCC), lung cancer and head and neck cancer, that change may be underway.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of woman with text.
Image of man with text.
Image of Staci.
Image of woman, with text.
Image of woman with text.
Image of man with text.
Ojjaara helps patients with myelofibrosis by reducing spleen size, easing symptoms, and improving anemia to boost independence from blood transfusions.
Image of Dr. Zhaoming Wang with text.
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.
Woman with text.